Trial reportJournal of diabetes research2025
Unveiling the Therapeutic Potential of Suyin Detoxification Prescription in Diabetic Nephropathy: A Comprehensive Study Integrating Clinical Efficacy, Network Pharmacology, and Molecular Mechanisms.
Trial report in Journal of diabetes research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy (DN) is a severe complication of diabetes, characterized by progressive renal dysfunction and proteinuria. Suyin Detoxification Prescription (SDP), a traditional Chinese medicine (TCM) formulation, has shown promising clinical efficacy in alleviating DN symptoms. This study is aimed at comprehensively evaluating the therapeutic effects of SDP through clinical observations, network pharmacology analysis, and molecular mechanism exploration. Methods: This study employed a randomized controlled trial combined with network pharmacology, pathological analysis, immunofluorescence, and Western blot to comprehensively investigate the therapeutic efficacy and mechanisms of SDP in DN treatment. Results: Clinical data revealed that SDP significantly reduces serum creatinine levels ( Conclusion: SDP exerts renal protective effects in DN through FXR activation, mitigating oxidative stress and inflammatory damage, while reducing proteinuria and renal function impairment, providing novel therapeutic strategies for DN management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.